Abstracts tagged "Disease Activity"

Abstract Number: 465 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Cutaneous Flares for Pediatric Lupus
Tamara Tanner¹, Marija Dionizovik-Dimanovski², Dawn Wahezi³ and Tamar Rubinstein³, ¹Albert Einstein College of Medicine/ Children's Hospital at Montefiore, Albert Einstein College of Medicine/ Children's Hospital at Montefiore, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: Exposure to sunlight has been proposed as a possible environmental trigger for lupus flares, particularly cutaneous disease. Contradictory findings exist regarding seasonal variation in…
Abstract Number: 882 • 2018 ACR/ARHP Annual Meeting
Predictors of Chronic Kidney Disease in US Veterans with Rheumatoid Arthritis
J. Steuart Richards¹, Richard Amdur², Grant W. Cannon³ and Gail S. Kerr⁴, ¹Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, ²Lead Biostatistician, Medical Faculty Associates Clinical Professor, Dept. of Surgery, George Washington University School of Medicine & Health Sciences, Washington, DC, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC
Background/Purpose: Chronic kidney disease (CKD) is a comorbidity that may affect patients with rheumatoid arthritis (RA). CKD restricts the use of disease modifying anti-rheumatic drugs…
Abstract Number: 1474 • 2018 ACR/ARHP Annual Meeting
Circulating Transfer RNA-Derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Qiong Wu, Quanhu Sheng, Joseph F. Solus, Kasey Vickers, Ryan Allen, Shilin Zhao, Yan Guo, Fei Ye, C Michael Stein and Michelle J. Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small RNAs (sRNAs) are important gene regulators and markers of disease. Transfer RNA (tRNA)-derived sRNAs (tDRs), including tRNA fragments (tRFs) and halves (tRHs), are…
Abstract Number: 1682 • 2018 ACR/ARHP Annual Meeting
Correlation between SLE Specific and Generic Health Related Quality of Life Surveys, and Their Association with Patient Global Rating of Change and Lupus Low Disease Activity State: A Longitudinal Study
Worawit Louthrenoo¹, Nuntana Kasitanon¹, Eric Morand² and Rangi Kandane-Rathnayake³, ¹Division of Rheumatology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: To determine the correlation between SLE-specific and generic patient reported outcomes measures (PROs), and to examine their associations with patients’ global rating of change…
Abstract Number: 2120 • 2018 ACR/ARHP Annual Meeting
CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
Jin Kyun Park¹, Ye Ji Lee², Ji Soo Park³, Eun Young Lee⁴, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Department of Immunology, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
CD47-Signal Regulatory Protein-Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus.Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease mediated by unbalanced activation of…
Abstract Number: 2493 • 2018 ACR/ARHP Annual Meeting
Features of Disease Severity Associated with Patient Satisfaction with Biologic Treatment: Results from the Abatacept Best Care Real-World Study
Boulos Haraoui¹, Janet E. Pope², Emmanouil Rampakakis³, Julie Vaillancourt³, Meryem Maoui⁴ and Louis Bessette⁵, ¹Université de Montréal, Montreal, QC, Canada, ²St. Joseph’s Health Care, London, ON, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Bristol-Myers Squibb, Montreal, QC, Canada, ⁵Laval University, Québec, QC, Canada
Background/Purpose: Patients satisfaction with their treatment is important for adherence to medications, particularly for chronic conditions such as rheumatoid arthritis (RA). The aim of this…
Abstract Number: 2860 • 2018 ACR/ARHP Annual Meeting
Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk^1,2, Michael Evans³, Julia Kay¹, Lisa Gale Suter⁴, Megan E. B. Clowse⁵, Esi Morgan⁶, Andreas Reimold⁷, Alex Limmani⁸, Tracy Johansson⁹, Lindsay Lewis⁹ and Jinoos Yazdany¹⁰, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, San Francisco, CA, ³University of California - San Francisco, San Francisco, CA, ⁴Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ⁵Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ⁶University of Cincinnati, Cincinnati, OH, ⁷Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ⁸Arthritis Centers of Texas, Dallas, TX, ⁹Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ¹⁰University of California, San Francisco, San Francisco, CA
Background/Purpose: Although national quality measures promote the measurement of disease activity (DA) in RA, the burden of DA in a population-based sample of RA patients…
Abstract Number: 71 • 2018 ACR/ARHP Annual Meeting
Association of Shared Epitope and Poor Prognostic Factors in RA
Evo Alemao¹, Joshua Bryson¹, Christine K Iannaccone², Michelle Frits², Nancy A. Shadick³ and Michael Weinblatt², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a strong genetic association between RA and human leukocyte antigen (HLA) regions, particularly HLA-DRB1 alleles with the shared epitope (SE). SE alleles…
Abstract Number: 483 • 2018 ACR/ARHP Annual Meeting
Correlation between Disease Activity and Hip Score in Patients with Rheumatoid Arthritis after Total Hip Arthroplasty
Hiroki Wakabayashi^1,2, Masahiro Hasegawa³ and Akihiro Sudo^4,5, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ²Orthopaedic Surgery, Mie University Graduate School of Medicine, Mie, Japan, ³Mie University Graduate School of Medicine, Tsu, Japan, ⁴Department of Orthopaedic surgery, Mie University Graduate School of Medicine, Tsu-city, Japan, ⁵Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: The Disease Activity Score including 28 joints (DAS28), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) were developed in…
Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks¹, Tracy Doyle², Jie Huang¹, Beatrice Pan², Elaine Fletcher², Ritu Gill³, Hiroto Hatabu², Mizuki Nishino⁴, David Murphy², Taysir Mahmoud², Christine K Iannaccone⁵, Michelle Frits², Bing Lu⁶, Ivan O. Rosas⁷, Paul Dellaripa², Michael E Weinblatt⁵, Elizabeth Karlson⁶ and Nancy A. Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Beth-Israel Deaconess Medical Center, Boston, MA, ⁴Dana-Farber Cancer Institute, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁷BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
Abstract Number: 1478 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Disability and Health-Related Quality of Life in Biologic-Treated Patients with Rheumatoid Arthritis in Persistent Moderate Disease Activity
Ian C. Scott^1,2, Julie Mount³, Jane Barry³ and Bruce Kirkham⁴, ¹Research Institute for Primary Care & Health Sciences, Primary Care Sciences, Keele University, Keele, United Kingdom, ²Department for Rheumatology, Haywood Hospital, Stoke on Trent, United Kingdom, ³Eli Lilly and Company, Basingstoke, United Kingdom, ⁴Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: A treat-to target (T2T) strategy is recommended for the management of rheumatoid arthritis (RA), with the target being remission or at least low disease…
Abstract Number: 1693 • 2018 ACR/ARHP Annual Meeting
Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
Melissa E. Munroe^1,2, Joel M. Guthridge¹, Rufei Lu^1,3, Joseph M. Kheir¹, Bolanle Adebayo¹, Susan R. Macwana¹, Hua Chen¹, Virginia C. Roberts¹, Mohan Purushothaman², Sanjiv Sharma², Teresa Aberle¹, Stan Kamp¹, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹ and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease marked by immune dysregulation. A comprehensive but cost-effective tool to track relevant mediators of altered…
Abstract Number: 2151 • 2018 ACR/ARHP Annual Meeting
The Impact of Obesity on SLE Disease Activity
Phildrich Teh¹, Bishoy Zakhary², Arezoo Haghshenas³ and Vaneet K. Sandhu³, ¹Internal Medicine, University of California, Riverside, Riverside, CA, ²Office of Research, Riverside University Health System, Moreno Valley, CA, ³Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Obesity is associated with increased disease severity in multiple autoimmune conditions, likely via formation of pro-inflammatory adipokines [1]. However, the role of obesity in…
Abstract Number: 2505 • 2018 ACR/ARHP Annual Meeting
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
Yuhan Zou¹, Peter P.M. Cheung^2,3, Lay Kheng Teoh⁴ and Manjari Lahiri^2,3, ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, ³Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore
Background/Purpose: Variable outcomes in early rheumatoid arthritis (ERA) may be explained by heterogeneous latent disease activity trajectories, the predictors of which are not well defined.…
Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Brian C. Sauer¹, Chia-Chen Teng, MS¹, Neil A. Accortt², David H. Collier², Tzu-Chieh Lin² and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…